Drug Trial Radar · NCT06008366
A Phase 1/2 Study of 7MW3711 in Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
281
Planned (sponsor's estimate)
Start
Sep 5, 2023
Primary completion
Aug 30, 2025
Study completion Feb 1, 2026
Sponsor
- Lead sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 23, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
7MW3711 is an antibody-drug conjugate(ADC) directed to a target wildly expressed on solid tumors. This is an open-label, multicenter, phase 1/2 study to evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 7MW3711 in subjects with advanced solid tumors.
Conditions
- Advanced Solid Tumor
Interventions
7MW3711 for injectionDrug
IV administration of 7MW3711, Q3W, 3 weeks a cycle
7MW3711 for injectionDrug
IV administration of 7MW3711, the dosage regimen including dosage and dosing frequency for cohort expansion is conformed on basis of the data in part 1
Primary outcomes
What the sponsor says the trial is designed to measure.
- evaluation of the incidence of adverse events (AEs) (part 1)Time frame: approximately up to 16 cycles, 21 days a cycle
- Identification of the MTD and /or RP2D of 7MW3711(part 1)Time frame: from Day1 to Day21 in cycle1 of part 1
- Overall response rate (ORR) evaluated by investigators based on RECIST version 1.1 in selected solid tumors(part 2)Time frame: approximately up to 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ethics Committee of Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.